NCT05681039
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
StatusActive, Not Recruiting
PhasePhase 2
SponsorM.D. Anderson Cancer Center
Primary completion (estimated)
At risk: Primary completion moved 2 years later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 19 versions: 8 with changes below, 11 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Nov 1, 2026 to Nov 1, 2028
- Eligibility criteria expanded, about 56 words
- Study description revised
- Minor Trial status changed: Recruiting → Active, Not Recruiting
- Site details revised
- Minor Site contact updatedv16
- Notable Primary completion date: Nov 1, 2025 to Nov 1, 2026
- Site contact updated
- Notable Primary completion date: Nov 1, 2024 to Nov 1, 2025v10
Show 2 earlier versionsHide 2 earlier versions
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jun 30, 2023 to Jun 2, 2023
- Site details revised
- Notable Primary endpoint revisedv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
The major pathological response rate after neoadjuvant atezolizumab and tiragolumab.
Timeframe: through study completion; an average of 1 year.
Arms and interventions
Neoadjuvant and AdjuvantExperimental
Drugs: Tiragolumab, Atezolizumab
Behavioral: Standard of Care, Questionnaires
Radiation: Cisplatin, Carboplatin
Sites
1 site in 1 country
- M D Anderson Cancer CenterHouston, Texas, United States